Our group has previously shown that therapeutic index and anti-cancer activity of potent cytokines such as IL-2 [11,15], IL-12 [39] or TNF [12,40], can be improved by fusing them to the L19 antibody in various formats. The gene discussed is IL2; the disease is cancer.